Tnxp stock price forecast short interest levels in TNXP are

Short interest levels in TNXP are hovering near multi‑month highs, adding pressure to the TNXP stock price forecast as traders debate near‑term squeezes. On balance, we think it's mildly positive that Tonix Pharmaceuticals Holding trimmed its cash burn by 13% over the last twelve months. But the revenue dip of 21% in the same period was a bit concerning. In light of the data above, we're fairly sanguine about the business growth trajectory. Clearly, however, the crucial factor is whether the company will grow its business going forward. So you might want to take a peek at how much the company is expected to grow in the next few years . L'azienda sta attualmente aspettando una decisione della FDA su TNX-102 SL per la gestione della fibromialgia, con una data PDUFA fissata per il 15 agosto 2025. Tonix ha anche diversi altri prodotti in sviluppo, tra cui TNX-1300 per intossicazione da cocaina e TNX-1500 per il rigetto dell'organo trapiantato. Inoltre, l'azienda ha ottenuto un contratto DoD del valore di fino a $34 milioni per lo sviluppo di TNX-4200. Analysts covering TNXP stock price forecast emphasize monitoring cash burn rate metrics in upcoming earnings to assess sustainability of R&D initiatives.